Krishnaswamy Yeleswaram, Chief Development Officer at Rapport Therapeutics, Inc. (RAPP), sold 19,865 shares at $34.98 ($696K) on 2026-04-10, disclosed to the SEC on 2026-04-14.
Scheduled sale ($696k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $34.98 | 500 | $17K | 2.5% |
| 2 | $34.97 | 9,165 | $321K | 46.1% |
| 3 | $35.08 | 10,200 | $358K | 51.4% |
| Total | $35.03 avg | 19,865 | $696K | 100% |
| Filing → |
| RAPP | SELL | 2026-04-21 | $809K | — | Filing → |
| RAPP | SELL | 2026-04-09 | $13K | — | Filing → |
| RAPP | SELL | 2026-03-26 | $607K | — | Filing → |